Why the study?
Does handle-region peptide (HRP) reduce pathologic retinal neovascularization in a mouse model of ischemic retinopathy?
Population
C57BL/6 neonatal mice with ischemia-induced retinal neovascularization
Comparison
Intraperitoneal injections of handle-region… vs Vehicle or control peptide
Design
Preclinical
Follow-up
Up to postnatal day 17
Authors
Loading...
HRP selectively attenuates pathologic neovascularization in mice; leaves open translation to human ischemic retinopathy trials.
Does handle-region peptide (HRP) reduce pathologic retinal neovascularization in a mouse model of ischemic retinopathy?
Inhibition of nonproteolytic activation of prorenin with HRP selectively attenuates pathologic retinal neovascularization and inflammation in a mouse model of ischemic retinopathy.
Satofuka et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: